Archeon Medical Raises $9 Mn Series A to Advance Emergency Ventilation Technology

EOlife® provides real-time feedback on ventilation during cardiac arrest treatment. The system is designed to help medical teams improve resuscitation and increase the chances of better survival and neurological outcomes.

The funding round was led by Newfund through its HEKA fund. New investors managed by Eiffel Investment Group and UI Investissement’s OSER BFC fund also participated, along with existing investors Majycc Innovation Santé and Karot Capital.

“This funding is a powerful accelerator for Archeon Medical. We are grateful to our investors and dedicated team, as this milestone represents a meaningful step forward for emergency healthcare,” said Alban de Luca, CEO of Archeon Medical. “These resources allow us to generate clinical evidence at scale and turn EOlife into the new global standard for emergency resuscitation.”

"During cardiac arrest, effective ventilation is critical to restoring oxygen delivery to the brain, yet it is still largely delivered without objective feedback,” said Anne-Sophie Saint-Martin, partner at Newfund. “Archeon makes ventilation measurable in real time, directly aligning with our HEKA fund’s focus on protecting brain health. With FDA clearance, growing traction among US EMS agencies, and the 2025 guidelines bringing renewed focus to ventilation, the US clinical program is an important next step in demonstrating EOlife’s value at scale.”

“Archeon Medical exemplifies the kind of innovation we seek in our healthcare portfolio. With EOlife, the company is developing a technology that addresses a critical need in emergency care,” said François-Xavier Durand Mille, Vice-President at Eiffel Investment Group. “We believe this solution has the potential to advance clinical practice and be adopted by emergency care systems across Europe and the United States.”

Archeon Medical develops technology for emergency medical care. Its EOlife® range helps emergency responders provide safer and more effective manual ventilation to patients experiencing cardiac arrest.

EOlife® gives healthcare professionals feedback during ventilation, helping them follow recommended medical guidelines and provide the right level of support during emergencies.

The award-winning EOlife® devices are FDA-cleared and CE-marked and are already used in clinical and educational settings around the world. The company says the technology is becoming a leading solution for emergency manual ventilation.

Read Also- Personio Acquires Circula to Bring HR, Payroll and Spend Management Together